ASA Gold and Precious Metals Ltd C.ASA

Primary Symbol: ASA

ASA Gold and Precious Metals Limited is a non-diversified, closed-end investment company. The Company's investment objective is long-term capital appreciation primarily through investing in companies engaged in the exploration for, development of projects or mining of precious metals and minerals. The Company invests approximately 80% of its total assets in common shares or securities convertible into common shares of companies engaged, directly or indirectly, in the exploration, mining or processing of gold, silver, platinum, diamonds or other precious minerals; held as bullion or other direct forms of gold, silver, platinum or other precious minerals; in instruments representing interests in gold, silver, platinum or other precious minerals, and/or in securities of investment companies, including exchange traded funds, or other securities. The Company’s investment adviser is Merk Investments LLC.

NYSE:ASA - Post by User

ASA Gold and Precious Metals Ltd > Valens and Medipharm long term outlook?

<< Previous

Bullboard Posts

Next >>

Post by Danweskeron Jul 16, 2019 7:19am

119 Views

Post# 29923689

Valens and Medipharm long term outlook?

Hey guys this was posted on the Medipharm bullboard too but wanted to get perspective from Valens board as well. What are your thoughts on both Valens and Medipharm, long term?

Legal forms of edible cannabis, cannabis extracts and cannabis topicals may be lawfully produced and sold as of October 17, 2019 in Canada, this will be great for extraction companies.

However, my concern is going forward in future, wouldn't large companies such as CGC and APHA have their own in house extraction facilities and how would this affect business to companies like Medipharm and Valens, would there still be a need or demand for them?

Thanks!

Dan

Read more at https://stockhouse.com/companies/bullboard?symbol=v.labs&postid=29923678#fsKSFKzPCvcSCrzT.99

<< Previous

Bullboard Posts

Next >>

Level up your trading with BMO InvestorLine’s enhanced features